Suma Krishnan Sells $8.98M of Krystal Biotech Inc (KRYS) — SEC Form 4, Sep 04, 2026
Open-Market Net Sale · SEC Form 4
−$8,982,986
10b5-1 Plan (Partial)
Equity position changed by -1.7%
Equity Position
1.49M sh
1,518,155 → 1,493,155
Equity Change
-1.7%
shares held after vs before
Filing Lag
0 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Suma Krishnan CIK 0001298711 |
Director
President
10% Owner
|
Suma Krishnan at Krystal Biotech Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
$34,273,413
More from this insider at Krystal Biotech Inc
| 2026-06-05 | Sell | -$7,702,825 | View |
| 2026-03-06 | Sell | -$6,580,270 | View |
| 2026-03-03 | Exercise | — | View |
| 2025-12-05 | Sell | -$11,007,332 | View |
| 2025-07-16 | Sell | -$5,395,000 | View |
Non-Derivative Securities Transactions
| Title | Date | Type | Shares | Price | Net Total | Post-Txn | Ownership |
|---|---|---|---|---|---|---|---|
| Common StockF1F2F3 | 2026-09-04 | S - Sale 10b5-1 | 520 D | $354.54 | -$184,361 | 1,326,625 | Direct |
| Common StockF4 | 2026-09-04 | S - Sale | 2,006 D | $355.57 | -$713,277 | 1,324,619 | Direct |
| Common StockF5 | 2026-09-04 | S - Sale | 3,267 D | $356.37 | -$1,164,254 | 1,321,352 | Direct |
| Common StockF6 | 2026-09-04 | S - Sale | 3,962 D | $357.57 | -$1,416,709 | 1,317,390 | Direct |
| Common StockF7 | 2026-09-04 | S - Sale | 3,180 D | $358.42 | -$1,139,777 | 1,314,210 | Direct |
| Common StockF8 | 2026-09-04 | S - Sale | 3,392 D | $359.39 | -$1,219,038 | 1,310,818 | Direct |
| Common StockF9 | 2026-09-04 | S - Sale | 2,320 D | $360.47 | -$836,281 | 1,308,498 | Direct |
| Common StockF10 | 2026-09-04 | S - Sale | 1,242 D | $361.61 | -$449,120 | 1,307,256 | Direct |
| Common StockF11 | 2026-09-04 | S - Sale | 1,992 D | $362.65 | -$722,404 | 1,305,264 | Direct |
| Common StockF12 | 2026-09-04 | S - Sale | 565 D | $363.34 | -$205,287 | 1,304,699 | Direct |
| Common StockF13 | 2026-09-04 | S - Sale | 1,329 D | $364.48 | -$484,390 | 1,303,370 | Direct |
| Common StockF14 | 2026-09-04 | S - Sale | 826 D | $365.41 | -$301,832 | 1,302,544 | Direct |
| Common StockF15 | 2026-09-04 | S - Sale | 399 D | $366.56 | -$146,256 | 1,302,145 | Direct |
Footnotes (18)
- F1
- The Reporting Person may be deemed to beneficially own shares of the Issuer's common stock directly owned by the Reporting Person's spouse, Krish S. Krishnan. Such shares and transactions by the Reporting Person's spouse are not included in this Form 4, as they are being reported separately on a Form 4 filed by her spouse. The Reporting Person disclaims beneficial ownership of such shares except to the extent of her pecuniary interest therein. Show more
- F2
- The sales reported were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025. The Rule 10b5-1 trading plan has reached the maximum number of shares to be sold under such plan and has terminated. Show more
- F3
- The transaction was executed in multiple trades ranging from $353.98 to $354.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F4
- The transaction was executed in multiple trades ranging from $354.98 to $355.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F5
- The transaction was executed in multiple trades ranging from $355.98 to $356.96. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F6
- The transaction was executed in multiple trades ranging from $356.99 to $357.97. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F7
- The transaction was executed in multiple trades ranging from $357.99 to $358.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F8
- The transaction was executed in multiple trades ranging from $358.99 to $359.98. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F9
- The transaction was executed in multiple trades ranging from $360.01 to $361.005. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F10
- The transaction was executed in multiple trades ranging from $361.02 to $362.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F11
- The transaction was executed in multiple trades ranging from $362.02 to $363.00. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F12
- The transaction was executed in multiple trades ranging from $363.05 to $364.01. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F13
- The transaction was executed in multiple trades ranging from $364.07 to $365.05. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F14
- The transaction was executed in multiple trades ranging from $365.07 to $366.03. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F15
- The transaction was executed in multiple trades ranging from $366.39 to $366.91. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. Show more
- F16
- Held by the Krishnan Spousal Trust, an irrevocable trust established by Mr. Krishnan for the benefit of Mrs. Krishnan who serves as a co-trustee and shares voting and investment power with a 3rd party co-trustee. Show more
- F17
- Held by the Suma Mani Krishnan Trust dated July 7, 2026. The Reporting Person is the grantor and trustee of the trust, has the power to revoke the trust, and has voting and investment power with respect to the shares held by the trust. Show more
- F18
- Held by the Krishnan Family Trust. The Reporting Person and her spouse are each joint beneficial owners of the trust with joint voting and investment control. Show more
Related filings at Krystal Biotech Inc
Institutional Holders
13F holders · Jun 30, 2026
424
institutional managers reporting a position
Largest by reported value
- Fmr Llc $1.64B
- Black Rock, Inc. $1.55B
- Avoro Capital Advisors Llc $1.07B
5%+ Holders · 13D/G
3 filers
-
Black Rock, Inc. 11.6%
-
Krish S. Krishnan 11.5%
Other insiders at Krystal Biotech Inc
GET /v1/forms/4/0001298711-26-000009
API docs
View Original SEC Filing